Numoda (Media speaks)
Zack's Investment Research(click here)
February 2012 numoda
Advaxis Reports Positive Phase II Trial Results
"...The study is designed to assess the safety and efficacy of ADXS-HPV for the treatment of CIN grade 2/3, which is late stage cervical dysplasia that requires surgery to prevent invasive cancer. Numoda Corporation is Advaxis’ strategic partner in the conduction and execution of this trial. "
February 2012 numoda
Advaxis Reports Positive Phase II Trial Results
"...The study is designed to assess the safety and efficacy of ADXS-HPV for the treatment of CIN grade 2/3, which is late stage cervical dysplasia that requires surgery to prevent invasive cancer. Numoda Corporation is Advaxis’ strategic partner in the conduction and execution of this trial. "
One Med Place(click here)
January 2012 numoda
Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preliminary Data
"Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reports that Thomas Moore, CEO & Chairman of Advaxis, was interviewed by Malini Chatterjee, Ph.D., Director of Research at OneMedPlace, to discuss the preliminary safety and survival data from the ongoing ADXS-HPV Phase 2 Trial in patients with recurrent/refractory cervical cancer in India that were presented at the World Cancer Immunotherapy Conference in San Diego on January 25, 2012.. "
January 2012 numoda
Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preliminary Data
"Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reports that Thomas Moore, CEO & Chairman of Advaxis, was interviewed by Malini Chatterjee, Ph.D., Director of Research at OneMedPlace, to discuss the preliminary safety and survival data from the ongoing ADXS-HPV Phase 2 Trial in patients with recurrent/refractory cervical cancer in India that were presented at the World Cancer Immunotherapy Conference in San Diego on January 25, 2012.. "
The Street (click here)
January 2012 numoda
Pinnacle Biologics, Inc. Announces The Successful Completion Of A Financing Round
" Led by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS announced today the succesful completion of a financing round, in a combination of Equity, and Debt Conversion. "
January 2012 numoda
Pinnacle Biologics, Inc. Announces The Successful Completion Of A Financing Round
" Led by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS announced today the succesful completion of a financing round, in a combination of Equity, and Debt Conversion. "
Med City News (click here)
December 2011 numoda
Numoda life science investment arm collaborates with stem cell technology company
- By Stephanie Baum
"Philadelphia technology company Numoda‘s life science investment arm, Numoda Capital Innovations, has collaborated with IntelliCell Bioscience, a New York-based company seeking to harvest adult adipose stem cells derived from fat in a cost-effective manner. "
December 2011 numoda
Numoda life science investment arm collaborates with stem cell technology company
- By Stephanie Baum
"Philadelphia technology company Numoda‘s life science investment arm, Numoda Capital Innovations, has collaborated with IntelliCell Bioscience, a New York-based company seeking to harvest adult adipose stem cells derived from fat in a cost-effective manner. "
Dow Jones Venture Wire (click here)
June 2011 numoda
With Drugs In Doubt, Some Biotechs Are Selling Out
- By Brian Gormely
"...Numoda now plans to develop Vitreosolve in the primary indication of vitreomacular adhesion and the secondary indication of inducing a posterior-vitreous detachment in the treatment of diabetic retinopathy. The firm plans new, placebo-controlled studies and is consulting drug-makers to find other ways to groom Vitreosolve for a sale. It aims to speed the auctioning process through technology from an affiliate, Numoda Technologies Inc., that enables potential bidders to see trial data as they are generated."
June 2011 numoda
With Drugs In Doubt, Some Biotechs Are Selling Out
- By Brian Gormely
"...Numoda now plans to develop Vitreosolve in the primary indication of vitreomacular adhesion and the secondary indication of inducing a posterior-vitreous detachment in the treatment of diabetic retinopathy. The firm plans new, placebo-controlled studies and is consulting drug-makers to find other ways to groom Vitreosolve for a sale. It aims to speed the auctioning process through technology from an affiliate, Numoda Technologies Inc., that enables potential bidders to see trial data as they are generated."
Dow Jones Venture Wire (click here)
March 2011 numoda
Numoda Capital Buys VitreoRetinal Assets, Seeks To Revive Vision Drug
- By Brian Gormely
"Numoda Capital Innovations is reviving an effort to develop a drug for the blinding disease diabetic retinopathy that stalled in the hands of venture-backed VitreoRetinal Technologies Inc."
March 2011 numoda
Numoda Capital Buys VitreoRetinal Assets, Seeks To Revive Vision Drug
- By Brian Gormely
"Numoda Capital Innovations is reviving an effort to develop a drug for the blinding disease diabetic retinopathy that stalled in the hands of venture-backed VitreoRetinal Technologies Inc."
January 2011 numoda
After announcing positive top-line results from a large, global Phase III clinical trial that Numoda managed and partially funded through an investment, stakeholders experienced a 46% gain in share price. Since the study began, $83MM in market value was created for our client, as well as a significant licensing deal.
After announcing positive top-line results from a large, global Phase III clinical trial that Numoda managed and partially funded through an investment, stakeholders experienced a 46% gain in share price. Since the study began, $83MM in market value was created for our client, as well as a significant licensing deal.
If you would like to learn more about how these results can benefit you please visit us at the JP Morgan 2011 Healthcare Conference. Contact Christopher Mather, SVP Business Affairs, for appointments.
Crain's Detroit Business (click here)
October 2010 numoda
MichBio Expo attendees hear ways to get VC funding for startups
- By Shawn White
..."There has been a decrease in number of biotech and medical investments overall," said Mary Schaheen, CEO of Philadelphia-based Numoda Corp. "But there have been a lot of very creative sources for funds: grants, alliances, high net worth investors and consolidation."...
October 2010 numoda
MichBio Expo attendees hear ways to get VC funding for startups
- By Shawn White
..."There has been a decrease in number of biotech and medical investments overall," said Mary Schaheen, CEO of Philadelphia-based Numoda Corp. "But there have been a lot of very creative sources for funds: grants, alliances, high net worth investors and consolidation."...
Pharmawire(click here)
October 2010
Marina retains Numoda for Phase Ib/IIa trial of lead compound; open to contact from other CROs for pivotal Phase IIb - CEO
-by Anusha Kambhampaty
...The company will work with Numoda for the 30 patient trial that will assess the knock-down of betacatenin
in the epithelial cells of the small and large intestine regions where beta-catenin is
known to be dysregulated in FAP...
October 2010
Marina retains Numoda for Phase Ib/IIa trial of lead compound; open to contact from other CROs for pivotal Phase IIb - CEO
-by Anusha Kambhampaty
...The company will work with Numoda for the 30 patient trial that will assess the knock-down of betacatenin
in the epithelial cells of the small and large intestine regions where beta-catenin is
known to be dysregulated in FAP...
World Market Media(click here)
July 2010Provectus Scores Points with Numoda Capital
- By Steven Michael King
July 2010Provectus Scores Points with Numoda Capital
- By Steven Michael King
... Numoda’s TruPoints platform already has an excellent reputation for helping numerous development stage biotech companies secure big pharma licensing agreements...
MedCityNews (click here)
July 2010Cleveland Clinic, Numoda partner to speed brain drugs to market
- By Mary Vanac
July 2010Cleveland Clinic, Numoda partner to speed brain drugs to market
- By Mary Vanac
...The goal is to speed effective neurological drugs to market and quickly weed out those that don’t work, while lowering the cost of drug development. ....
July 2010
Dow Jones Venture Wire (click here)
June 2010
Numoda Forms Cleveland Clinic Alliance; Deal Will Feed Venture Arm
- By Brian Gormely
June 2010
Numoda Forms Cleveland Clinic Alliance; Deal Will Feed Venture Arm
- By Brian Gormely
...Numoda said its technology and services can also help companies catch and fix problems that are occurring in clinical studies. Numoda will also provide researchers at Cleveland Clinic's Neurological Institute with information systems, reporting engines and administrative tools to help improve patient recruitment, budgeting and data flow. ....
Venture Capital Dispatch - WSJ (click here)
January 2010
JPMorgan Conference Lifts Biotech VC Hopes For Pharma Deals
- By Brian Gormely
January 2010
JPMorgan Conference Lifts Biotech VC Hopes For Pharma Deals
- By Brian Gormely
...Pharmaceutical companies at the conference were looking to spin products out as well as bring them in, said Terrance McGovern, managing director, Numoda Capital Innovations, an investment affiliate of Numoda Corp. ....
Dow Jones Venture Wire (click here)
August 2009
MediQuest Therapeutics Takes Streamlined Route To VC Liquidity
- By Brian Gormely
August 2009
MediQuest Therapeutics Takes Streamlined Route To VC Liquidity
- By Brian Gormely
...Numoda Capital also works with these companies to help them find strategic partners. The group aims to connect MediQuest with pharmaceutical companies interested in licensing Vascana and other pipeline drugs....
The Wall Street Journal (click here)
April 2009
Clinical Trials Manager Heads Into VC
- By Scott Austin
April 2009
Clinical Trials Manager Heads Into VC
- By Scott Austin
...Numoda’s track record of helping companies reduce the cost and risk of drug development should appeal to investors...
Dow Jones Venture Wire (click here)
April 2009
Numoda Seeks $150M Debut Health Fund
- By Brian Gormely
April 2009
Numoda Seeks $150M Debut Health Fund
- By Brian Gormely
...“From a financial perspective, we can de-risk the process,” Schaheen said. “Our job is to get time, quality and
money in balance.”...
money in balance.”...
C.E. Unterberg Business Analyst (click here)
June 2007
June 2007
...Enrollment nearing completion....numoda
Harvard Business Review (click here)
October 2006
...Managing risk and rewarding risk taking, integrating the skills and capabilities that reside in a range of disciplines...
October 2006
...Managing risk and rewarding risk taking, integrating the skills and capabilities that reside in a range of disciplines...
Charite Artificial Spinal Replacement Disc approved
by U.S. regulators within a year. (click here)
...for a recently concluded medical device study, sponsored by DePuy Spine (formerly Link Spine Group). This new prosthesis is an artificial spinal disc that provides a wider range of motion for the patient. The procedure is expected to replace spinal fusion surgery.
by U.S. regulators within a year. (click here)
...for a recently concluded medical device study, sponsored by DePuy Spine (formerly Link Spine Group). This new prosthesis is an artificial spinal disc that provides a wider range of motion for the patient. The procedure is expected to replace spinal fusion surgery.
Numoda Home
Numoda Services
Numoda About you
Numoda About us.
Numoda Media.
No comments:
Post a Comment